Proton pump inhibitors feature well-characterized pharmacological mechanisms, with intragastric pH serving as a PD biomarker closely correlated with clinical endpoints. Mechanism-driven PK/PD models are deployed to screen optimal clinical dosing regimens and support applications for a Phase II trial waiver, enabling direct progression to Phase III pivotal trials and shortening global drug development timelines.